LSU Health New Orleans

Departments & Centers | Contact | Donate

Administration Basic Sciences Clinical Sciences Centers of Excellence


Pediatric Hematology and Oncology Trials

For more information, contact:
Lolie Yu, MPH, MD, at (504) 896-9740
Stephanie Sonnier, RN, at (504) 894-5377

Last Updated - July 2, 2012


AALL08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

AALL0433: Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies

AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)

AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND#76431, NSC#617807)

AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum


AAML08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)

ACCL0933: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)


ANBL00B1: Neuroblastoma Biology Studies

ANBL0032: Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

ANBL0532: NOTES III Randomized Trial of Single vs. Tandem Myeloablative as Consolidation Therapy for High-Risk Neuroblastoma

ANBL1021: Feasibility/Phase II Study of hu14.18-IL2 immunocytokine + GM-CSF and Isotretinoin in Patients with Relapsed or Refractory Neuroblastoma

Wilms Tumor / Renal

9442: National Wilms Tumor Late Effects Study

AREN0532: Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

AREN0321: Treatment of High Risk Renal Tumors

AREN0533: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors

AREN0534: Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor

Brain Tumor / Medulloblastoma

ACNS02B3: A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens

ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A NOTES III Double Randomized Trial

ACNS0332: Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients

ACNS0333: Treatment of Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation

ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

ALTE07C1: Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer

Rare Tumor

ABTR01B1: A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors


AHEP0731: Treatment of Children with All Stages of Hepatoblastoma

Ewing Sarcoma

AEWS0331: European Ewing Tumor Working Initiative of National Groups Ewing Tumor Studies 1999 (EURO-E.W.I.N.G. 99)

AEWS1031: A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma.


ARST0531: Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS).

ARST08P1: A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma

ARST0921: A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temsirolimus (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma

D9902: A COG Soft Tissue Sarcoma Biology and Banking Protocol


ACCRN07: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)

ALTE03N1: Key Adverse Events after Childhood Cancer

ACCL1031: A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation

ACCL0431: A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children

ACCL05C1: A Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy

ACCL0934: A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)